| Document |
Document Title |
|
JP4491131B2 |
Disclosed are thiazolobenzoheterocycles of the general formulaIncluding their isomers, racemates, enantioners and salts thereof, as well as processes for preparing these compounds and medicaments containing them. Also disclosed are novel...
|
|
JP2010138208A |
To provide a pharmaceutically refined formulation containing olanzapine. The formulation includes olanzapine pamoate or its solvate. The formulation exhibits a prolonged sustained release of more than 7 days and a burst release of less t...
|
|
JP2010520237A |
The present invention is directed to substituted benzodiazepinones, benzoxazepinones and benzothiazepinones compounds that are sodium channel blockers useful for the treatment of chronic and neuropathic pain. The compounds of the present...
|
|
JP4469424B2 |
A compound of the formulawherein the substituents are defined as in the specification and their pharmaceutically acceptable salts having NOS and ROS activity.
|
|
JP2010514693A |
The invention provides novel compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.
|
|
JP2010513357A |
Compounds of the formula (I) are provided: wherein V, W, X, Y, Z, R3, R4, R5, R6, R7 and m are as defined in the specification; and pharmaceutically acceptable salts and prodrugs thereof. The compounds may be useful in the treatment or p...
|
|
JP4457017B2 |
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/...
|
|
JP2009530390T5 |
|
|
JP4448134B2 |
Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutic...
|
|
JP2010065038A |
To provide conjugates of fatty alcohols and pharmaceutical agents useful in treating cancer, viral deseases, psychiatric disorders.Compositions (1) are expressed by chemical formula (1). In the formula, R is an 8-26C fat group of a fatty...
|
|
JP4440257B2 |
Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula I: which are used to m...
|
|
JP4440642B2 |
The subject invention provides compounds having the structure: wherein R1 is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R2 is hydrogen, or a substituted o...
|
|
JP2010507644A |
The present invention relates to new sulfonamide derivatives of formula (I) wherein R1-R5 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective an...
|
|
JPWO2008053913A1 |
General formula (I):[In the formula, R1Is the expression:(R26And R28Are lower alkyloxys, etc., each of which may be substituted independently; n1Is a group represented by (an integer of 0 to 3); Z may be substituted or may intervene with...
|
|
JP2010505860A |
This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This...
|
|
JP4422670B2 |
The present invention relates to compounds of the formula I wherein A 1 , A 2 , R 1 , R 2 , R 3 , X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for...
|
|
JP2010031045A |
To provide a method for treating Alzheimer disease by using substituted cyclic amine BACE-1 inhibitors having a benzamide or a pyridinecarboxamide substituent.There are disclosed compounds of formula I or a pharmaceutically acceptable sa...
|
|
JP4411204B2 |
N-((N-(4-Amidinobenzyl)-N-methylcarbamoyl)-alkyl)-arylsulfon
amides (I) are new. Aryl sulfonamide derivatives of formula (I) and their acid addition salts are new. R1 = aromatic nucleus (optionally substituted by one or more of halo, 1-3...
|
|
JP4410328B2 |
A method of preparing oxoquazepam shown by the following formula (2), which comprises reacting 2,2,2-trifluoroethyl trifluoromethanesulfonate with 7-chloro-1,3-dihydro-5-(2-fluorophenyl)-2H-1,4-benzodiazepin
-2-one shown by the following...
|
|
JP2010013473A |
To provide a medicine having 5-HT6 receptor antagonist activity and useful for prevention and treatment of obesity, diabetes mellitus type 2 and/or central nervous system disorder.The substituted sulfonamide compound is represented by ge...
|
|
JP2010006838A |
To provide a more potent inhibitor for the vitronectin receptor than for the fibrinogen receptor.This invention provides a compound of formula (I) which have pharmacological activity for the inhibition of the vitronectin receptor and is ...
|
|
JPWO2008023847A1 |
The following general formula (II), (In the formula, R11Represents a hydrogen atom or an alkyl group having 1 to 8 carbon atoms, and R21Represents an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, an ...
|
|
JP2010500341A |
The present invention relates to new heterocyclic compounds containing nitrogen atoms or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same for treatment...
|
|
JP4394953B2 |
Compounds of Formula I including all geometric and stereoisomers, N-oxides, and agriculturally suitable salts thereof, are disclosed which are useful as invertebrate pest control agents wherein A, B, J, K, L and R3 are as defined in the ...
|
|
JP4390024B2 |
|
|
JP2009544579A |
Certain substituted benzyl amine compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.
|
|
JP4380814B2 |
1-Benzoyl-4-aminoacyl-7-phenyl-1,4-diazepine derivatives (I) are new. Also new are four classes of intermediates. 1,4-Diazepine derivatives of formula (I) and their acid addition salts are new. Ph1 = phenyl substituted by R2 and R3; Ph2 ...
|
|
JP2009542707A |
Certain substituted butyl and butynyl benzyl amine compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.
|
|
JP2009542706A |
Certain substituted benzamide compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.
|
|
JP2009541217A |
A compound of the formula (I): and pharmaceutically acceptable salts thereof, wherein: R2, R3, R4 and R5 are independently selected from the group consisting of H, C1-7 alkoxy, amino, halo or hydroxy; Y is -CRRC2-(CH2)m-, where m is 0 or...
|
|
JP4373926B2 |
Compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, and X are as defined herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof, pharmaceutical compositions containing such compounds, and methods ...
|
|
JP2009269856A |
To prevent an abnormal behavior occasionally occurring subsequent to the administration of an influenza treatment drug such as oseltamivir.The agent of preventing abnormal behavior contains as an active ingredient at least one compound s...
|
|
JPWO2007148711A1 |
The following formula (I), which is useful as an active ingredient of a drug for the prevention and / or treatment of diseases caused by activation of STAT6 and / or NF-κB:[R1, R2, R3And R4Is a hydrogen atom, a halogen atom, a cyano gro...
|
|
JP4365102B2 |
The present invention relates to a novel sulfonamide derivatives and novel intermediates thereof, preparation thereof, and a pharmaceutical composition comprising the same, and more particularly, to novel sulfonamide derivatives and inte...
|
|
JP4366443B2 |
The present invention provides an sulfonamide derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergi...
|
|
JP4364637B2 |
The invention relates to novel benzo-fused heterocycles and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the com...
|
|
JP4361727B2 |
Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutical...
|
|
JP4359859B2 |
The present invention relates to novel compounds of general formula (I) which can be used for treating medical disorders resulting from a deficiency in growth hormone.
|
|
JP2009538270A |
The present invention provides novel compounds that inhibit cell proliferation, in particular through the disruption of chromosome segregation and uses of these compounds for treating, ameliorating or preventing diseases, conditions or d...
|
|
JP2009538330A |
The invention relates to salts of 1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e
][1,4]diazepin-3-yl)-urea and crystalline forms thereof, their production and usage, and pharmaceutical preparations containing such salts and...
|
|
JP2009537616A |
The present invention relates to 2-alkoxy-3,4,5-trihydroxyalkylamide derivatives, to pharmaceutical compositions comprising such compounds, to methods of treatment comprising administering such compounds, to processes for the preparation...
|
|
JP4352001B2 |
The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is...
|
|
JP4350512B2 |
This invention provides a method of treating pain in a mammal that includes administering to a mammal in need of such treatment a pain treating effective amount of a compound of the formula (I): where R1 is H, alkyl or phenylalkyl; R2 is...
|
|
JP4349657B2 |
Aza- and diazacyclohexane and -cyclooctane compounds of the following formula:where Ar1, A, B and Ar2 have the meanings stated in the description have a high affinity for the dopamine D3 receptor and can therefore be used to treat disord...
|
|
JP4338305B2 |
This invention relates to new compounds selected from those of general formula (I), or a pharmaceutically acceptable salt, ester or prodrug form thereof, wherein D, E, and G are N or CH, which serve as vasopressin agonists and are useful...
|
|
JP4336107B2 |
The present invention relates to diazepine derivatives of formula (I) wherein R represents hydrogen or C1-4 alkyl; R1 represents hydrogen or C1-4 alkyl; R2 represents trifluoromethyl, C1-4 alkyl, C1-4 alkoxy, trifluoromethoxy or halogen;...
|
|
JP4327915B2 |
The present invention discloses a sulfonamide derivative represented by the following formula (1): wherein A represents a nitrogen atom, -CH=, etc.; Z represents an oxygen atom, etc.; Ar<1> represents an aryl group, etc.; Ar<2> represent...
|
|
JP2009530352A |
This invention relates to novel guanidine derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for ther...
|
|
JP2009530231A |
The present invention relates generally to novel therapeutic compounds and AXOR 109 agonists, and processes for the manufacture and use of the same.
|
|
JP2009530390A |
Diaza heterocyclic amide derivatives according to Formula (I) have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: where R5, R6, R7, R8, R9, R10, m, Q, X, and Y are set forth ...
|
